A practical reference on angiotensin IV: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-05-03. Anything still debated is marked as such rather than presented as settled.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Development of dihexa followed from studies on angiotensin IV analogs and their effects on learning and memory. Researchers sought compounds with improved metabolic stability and brain penetration compared with natural peptides. In preclinical reports, dihexa was associated with changes in synaptic connectivity and performance on spatial tasks. These findings generated interest in its potential as a cognitive research tool. The work remains largely preclinical, and independent replication has been limited.
Regulatory and commercial contexts differ from clinical medicine. Dihexa is not approved as a drug by major agencies, and no published human trials establish its safety or efficacy. It is often sold as a research chemical labeled for laboratory use only. Suppliers may provide certificates of analysis, but purity and identity depend on the specific batch. Legal status varies by country and may treat such compounds as unapproved substances for human consumption.
Dihexa is a synthetic peptidomimetic derived from angiotensin IV, a naturally occurring peptide fragment. It was created as a research compound to explore central nervous system signaling rather than as an approved therapeutic. Early work described it as a small, orally available molecule in rodent studies. Its structure combines tyrosine, isoleucine, and aminohexanoic acid components with a hexanoic acid cap. The compound is commonly referred to by the research code PNB-0408.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide analog | Structural features include amino acid residues and a hexanoic acid group. |
| Common synonyms | PNB-0408; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Names vary by source and should be verified. |
| Origin | Angiotensin IV research | Developed as a modified analog in academic laboratories. |
| Primary research focus | Synaptic growth and cognition | Studied mainly in cultured neurons and rodent models. |
| Regulatory status | Not approved as a drug | No accepted human therapeutic or supplement status. |
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
3-hydroxydecanoyl-(acyl-carrier-protein) dehydratase (EC 4.2.1.60, D-3-hydroxydecanoyl-[acyl-carrier protein] dehydratase, 3-hydroxydecanoyl-acyl carrier protein dehydrase, 3-hydroxydecanoyl-acyl carrier protein dehydratase, β-hydroxydecanoyl thioester dehydrase, β-hydroxydecanoate dehydrase, beta-hydroxydecanoyl thiol ester dehydrase, FabA, β-hydroxyacyl-acyl carrier protein dehydratase, HDDase, β-hydroxyacyl-ACP dehydrase, (3R)-3-hydroxydecanoyl-[acyl-carrier-protein] hydro-lyase) is an enzyme with systematic name (3R)-3-hydroxydecanoyl-(acyl-carrier protein) hydro-lyase. This enzyme catalyses the following chemical reaction
Valve licensed the use of Portal to Headup Games and Clockstone Software, the developers of Bridge Constructor, to develop Bridge Constructor Portal. The game follows the same type of gameplay as Bridge Constructor, where players are tasked to create a bridge from a limited set of parts to cross a river or chasm, using physics simulations to test if the bridge will hold up against traffic crossing it. Bridge Constructor Portal adds in elements from the Portal series, such as portals, as part of the construction challenge. The game is set within Aperture Laboratories, with the puzzles monitored by GLaDOS. The game released on December 20, 2017, for personal computers and mobile devices, and later in 2018 for PlayStation 4, Xbox One, and Nintendo Switch consoles.
== Adverse effects == Adverse effects from sitagliptin are similar to placebo, except for rare nausea, common cold-like symptoms, and photosensitivity. It does not increase the risk of diarrhea. No significant difference exists in the occurrence of hypoglycemia between placebo and sitagliptin. In those taking sulphonylureas, the risk of low blood sugar is increased. The existence of rare case reports of kidney failure and hypersensitivity reactions is noted in the United States prescribing information, but a causative role for sitagliptin has not been established. Several postmarketing reports of pancreatitis (some fatal) have been made in people treated with sitagliptin and other DPP-4 inhibitors, and the US FDA package insert carries a warning to this effect, although the causal link between sitagliptin and pancreatitis has not yet been fully substantiated. One study with lab rats published in 2009 concluded that some of the possible risks of pancreatitis or pancreatic cancer may be reduced when it is used with metformin. However, while DPP-4 inhibitors showed an increase in such risk factors, as of 2009, no increase in pancreatic cancer has been reported in individuals taking DPP-4 inhibitors. In 2015, the US Food and Drug Administration (FDA) added a new warning and precaution about the risk of "severe and disabling" joint pain to the labels of all DPP-4 inhibitor medicines.
==== Printer ink ==== Surfactants regulate the consistency of ink in inkjet printers. An insufficient amount of surfactants results in clumping of the color pigments, whereas an excessive amount renders the ink overly fluid during printing.
Sources: en.wikipedia.org
The bacterial one-hybrid (B1H) system is a method for identifying the sequence-specific target site of a DNA-binding domain. In this system, a given transcription factor (TF) is expressed as a fusion to a subunit of RNA polymerase. In parallel, a library of randomized oligonucleotides representing potential TF target sequences are cloned into a separate vector containing the selectable genes HIS3 and URA3. If the DNA-binding domain (bait) binds a potential DNA target site (prey) in vivo, it will recruit RNA polymerase to the promoter and activate transcription of the reporter genes in that clone. The two reporter genes, HIS3 and URA3, allow for positive and negative selections, respectively. At the end of the process, positive clones are sequenced and examined with motif-finding tools in order to resolve the favoured DNA target sequence.
== Isobaric carrier concept == TMT tags are commonly used to label samples of equal abundance. If one of the labeled samples is more abundant, however, it may increase the sensitivity of the analysis for all samples. Such isobarically labeled samples are referred to as isobaric carriers. They were introduced for single-cell protein analysis by mass spectrometry, and have found many other applications.
== Biological function and disease relevance == In E. coli, OmpT is a housekeeping protease that degrades foreign peptide material that the bacteria encounters. Because of its ability to cleave peptides present in its surrounding environment, OmpT is associated with several pathologies.
After the internal structure of the atom was probed, amateur Dutch physicist Antonius van den Broek proposed in 1913 that the nuclear charge determined the placement of elements in the periodic table. The New Zealand physicist Ernest Rutherford coined the word "atomic number" for this nuclear charge. In van den Broek's published article he illustrated the first electronic periodic table showing the elements arranged according to the number of their electrons. Rutherford confirmed in his 1914 paper that Bohr had accepted the view of van den Broek. The same year, English physicist Henry Moseley using X-ray spectroscopy confirmed van den Broek's proposal experimentally. Moseley determined the value of the nuclear charge of each element from aluminium to gold and showed that Mendeleev's ordering actually places the elements in sequential order by nuclear charge. Nuclear charge is identical to proton count and determines the value of the atomic number (Z) of each element. Using atomic number gives a definitive, integer-based sequence for the elements. Moseley's research immediately resolved discrepancies between atomic weight and chemical properties; these were cases such as tellurium and iodine, where atomic number increases but atomic weight decreases. Although Moseley was soon killed in World War I, the Swedish physicist Manne Siegbahn continued his work up to uranium, and established that it was the element with the highest atomic number then known (92).
==== Mental fitness ==== Mental fitness is a mental health movement that encourages people to intentionally regulate and maintain their emotional wellbeing through friendship, regular human contact, and activities that include meditation, calming exercises, aerobic exercise, mindfulness, having a routine and maintaining adequate sleep. Mental fitness is intended to build resilience against every-day mental and potentially physical health challenges to prevent an escalation of anxiety, depression, and suicidal ideation. This can help people, including older adults with health challenges, to more effectively cope with the escalation of those feelings if they occur.
Sources: en.wikipedia.org
While contemporary models, such as the Big Five or psychometric adaptations such as Hans Eysenck's PEN model, often define these terms through social behavioural traits (such as shyness, gregariousness, sociability and impulsivity), Jung defined them as 'directional orientations of libido.' Modern theories often stay true to behaviourist means of describing such a trait (sociability, talkativeness, assertiveness etc.), whereas Jungian introversion and extraversion are expressed as a perspective: introverts interpret the world subjectively, whereas extraverts interpret the world objectively. Jung also posited different functions of consciousness: two perceiving/non-rational functions: sensation and intuition; and two judging/rational functions: thinking and feeling. These are modified (or combined with) the two main attitudinal types (introversion and extroversion) to produce eight distinct psychological types: extraverted sensing, introverted sensing, extraverted intuiting, introverted intuiting, extraverted thinking, Introverted thinking, extraverted feeling, and introverted feeling. Whilst Jung posits these different types, he argues that it is rare that a person is an absolutely 'pure' type, and more likely a person has a main function, but also has a secondary function which blurs the picture. The secondary type is known as the 'inferior type' and is often associated with the shadow.
The jury called it a "descriptive word" which "in terms of its content as well as its length, is a symbol and an ironic form of commentary for the political events of this year, characterized by the very long campaign for the presidential election, the challenges of the voting process, and its reiteration." The tongue twister Rhabarberbarbarabarbarbarenbartbarbierbier gave rise to the novelty song Barbara's Rhubarb Bar (Barbaras Rhabarberbar), which became a viral phenomenon in 2024. Another long word, coming in at 67 letters, is Grundstücksverkehrsgenehmigungszuständigkeitsübertragungsverordnung, meaning “the rule on the transfer of jurisdiction in authorizing a land plot transaction.” The longest word in the Duden is "Aufmerksamkeitsdefizit-Hyperaktivitätsstörung" (ADHD) with 42 letters.
The simplest way to do this is to remove the gene and see what phenotype develops compared to the wild type form. Any differences are possibly the result of the missing gene. Unlike mutagenisis, genetic engineering allows targeted removal without disrupting other genes in the organism. Some genes are only expressed in certain tissues, so reporter genes, like GUS, can be attached to the gene of interest allowing visualization of the location. Other ways to test a gene is to alter it slightly and then return it to the plant and see if it still has the same effect on phenotype. Other strategies include attaching the gene to a strong promoter and see what happens when it is overexpressed, forcing a gene to be expressed in a different location or at different developmental stages.
== Production == In November 2024, Amazon MGM Studios was developing an action thriller film titled The Runner with Kevin Macdonald directing, Mark Gibson writing the script, and Gal Gadot starring. Principal photography began on 22 April 2025, in London and wrapped filming around early July 2025. London locations lensed include: Regent's Canal and St Pancras Way, in the London Borough of Camden; Kentish Town; Canary Wharf; Covent Garden; and Hampstead Heath. Some filming was on unclosed live streets, with real crowds and hidden cameras. The setting of Maia's route begins around Hampstead Heath, to Kentish Town, then along Regent's Canal, then down St Pancras Way, then toward King's Cross, London, and London King's Cross railway station. Later, in The City of London, sites include: Watling Street, Coleman Street, and King's Arms Yard. Later, in Canary Wharf and around the Thames river: Millennium Bridge, Waterloo Bridge and HMS Belfast. Through April and May 2025, eight pro-Palestinian protesters in total were arrested for disrupting the Central London set of the film. The film's production schedule, however, was not affected. The Metropolitan Police stated in a news release that the demonstrations were “solely because an actress involved in the production is Israeli." Gadot, who previously served in the IDF for two years, has been described as "vocal in her support of Israel".
Sources: en.wikipedia.org
Dihexa is a synthetic peptide-like compound studied primarily in preclinical models. It is often classified as an angiotensin IV analog and has been investigated for effects on neuronal connectivity. It is not an approved drug or dietary supplement.
The exact mechanism is uncertain. Some research proposes activation of hepatocyte growth factor/c-Met signaling, while other evidence implicates insulin-regulated aminopeptidase. Multiple pathways may contribute, depending on the experimental system.
Published large-scale human trials are lacking. Most available data come from cell cultures and animal studies. As a result, human safety, appropriate dosing, and clinical effectiveness are not established.
Dihexa is a synthetic peptidomimetic related to angiotensin IV. It is studied in preclinical research for effects on synaptic signaling and cognition. It is not an approved medication.